Summary of Demographics and Baseline Characteristics
(All Subjects)
Variables
Placebo
Xanomeline
Low Dose
Xanomeline
High Dose
Total
Age
n
86
84
84
254
Mean
75.21
75.67
74.38
75.09
SD
8.59
8.29
7.89
8.25
Median
76
77.5
76
77
Min
52
51
56
51
Max
89
88
88
89
Age group 1
<65
14 (16.28%)
8 (9.52%)
11 (13.1%)
33 (12.99%)
]65-80[
42 (48.84%)
47 (55.95%)
55 (65.48%)
144 (56.69%)
>80
30 (34.88%)
29 (34.52%)
18 (21.43%)
77 (30.31%)
Sex
Female
53 (61.63%)
50 (59.52%)
40 (47.62%)
143 (56.3%)
Male
33 (38.37%)
34 (40.48%)
44 (52.38%)
111 (43.7%)
Race
White
78 (90.7%)
78 (92.86%)
74 (88.1%)
230 (90.55%)
Black or African American
8 (9.3%)
6 (7.14%)
9 (10.71%)
23 (9.06%)
American Indian or Alaska
Native
NA
NA
1 (1.19%)
1 (0.39%)
Duration of Disease (Months)
n
86
84
84
254
Mean (SD)
42.65 (30.24)
48.69 (29.58)
40.51 (24.69)
43.94 (28.4)
Median (min,max)
35.3
(7.2,183.1)
40.25
(7.8,130.8)
35.95 (2.2,135)
36.25
(2.2,183.1)
Disease duration Group 1
>=12
81 (94.19%)
81 (96.43%)
80 (95.24%)
242 (95.28%)
<12
5 (5.81%)
3 (3.57%)
4 (4.76%)
12 (4.72%)
